Extraordinary performance in European Life Sciences VC funding continues

The aggregated venture capital funding of Life Sciences companies in Europe has significantly increased during the second quarter of 2021, reaching EUR 7,330 million so far (EUR 3,825 million in the first half of 2020). The total funding volume in the first half of 2021 is 93% higher than in the first half of 2020.

With 485 Deals in the first half of 2021 compared to 512 Deals in the same period of the previous year, the total number of deals decreased. However, the average deal size more than doubled (EUR 15.1 million in the first half of 2021 compared to EUR 7.5 million in the first half of 2020).

About FCF Life Sciences

FCF Life Sciences advises leading healthcare companies in Europe on financing transactions (equity, debt, and licensing) with regional and international investors. Our team consists of science-driven industry and finance experts with a strong track record in managing financing processes. We thrive to maximize the efficiency in the fundraising process and increase its closing probability.

Learn more about FCF Life Sciences, click here.

We closely track the activity in the financial markets and are passionate about capital markets research. Not every idea or research question make it into the final selection for our publications. However, we generate interesting information on financing trends in Life Sciences sector, which we would like to share in our blog.

To hear from us on the latest insights, please sign up here:

[a-zA-Z0-9_.-]
[a-zA-Z0-9_.-]
[a-zA-Z0-9]
[a-zA-Z0-9]